We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Intravesical Injection of Botox for Treating Therapy Refractory Overactive Bladder in Females

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01042119
Recruitment Status : Completed
First Posted : January 5, 2010
Last Update Posted : June 24, 2010
Sponsor:
Information provided by:
University of Zurich

Brief Summary:

The neurotoxin Botox (botulinum neurotoxin type A) is shown to be effective in the treatment of therapy refractory overactive bladder syndrome. Our data suggests a longer during efficacy than known from the use in striated muscle.

The aim of our study is to analyze short- and longterm efficacy after Botox treatment and to evaluate risk factors for non-responders and side effects such as urinary retention.


Condition or disease
Overactive Bladder Syndrome

Study Type : Observational
Estimated Enrollment : 200 participants
Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Short- and Longterm Results After Intravesical Injection of Botulinum Neurotoxin Type A for Treating Therapy Refractory Overactive Bladder in Females - a Retrospective Study
Study Start Date : January 2010
Primary Completion Date : June 2010
Study Completion Date : June 2010

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Group/Cohort
Botox
patients who received intravesical injections of botulinum neurotoxin type A



Primary Outcome Measures :
  1. duration of effect of Botox [ Time Frame: 1 year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
patients who received at our clinic treatment with intravesical injection of Botox for idiopathic overactive bladder syndrome
Criteria

Inclusion Criteria:

  • intravesical treatment with Botox at our clinic

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01042119


Locations
Switzerland
University Hospital of Zurich, Clinic for Gynaecology
Zurich, Switzerland, 8091
Sponsors and Collaborators
University of Zurich
Investigators
Principal Investigator: David A Scheiner, MD University Hospital of Zurich, Clinic for Gynaecology

Responsible Party: Scheiner, David, Dr. med., University Hospital of Zurich, Clinic for Gynaecology
ClinicalTrials.gov Identifier: NCT01042119     History of Changes
Other Study ID Numbers: FHKUSZ15-2009
First Posted: January 5, 2010    Key Record Dates
Last Update Posted: June 24, 2010
Last Verified: June 2010

Keywords provided by University of Zurich:
botulinum neurotoxin type A
BoNT/A
Botox
overactive bladder syndrome

Additional relevant MeSH terms:
Urinary Bladder, Overactive
Urinary Bladder Diseases
Urologic Diseases
Lower Urinary Tract Symptoms
Urological Manifestations
Signs and Symptoms
Botulinum Toxins, Type A
onabotulinumtoxinA
abobotulinumtoxinA
Neuromuscular Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Acetylcholine Release Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents